Litcius/Paper detail

Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings

Andrew Blauvelt, Nianwen Shi, Najwa Somani, Russel Burge, Baojin Zhu, Terri Ridenour, Carolyn R. Lew, Nicole M. Zimmerman, Bilal Atiya, Mwangi J. Murage

2021Journal of the American Academy of Dermatology19 citationsDOI

Topics & Concepts

SecukinumabIxekizumabMedicineDiscontinuationHazard ratioOdds ratioInternal medicineLower riskPsoriasisPsoriatic arthritisDermatologyConfidence intervalPsoriasis: Treatment and PathogenesisSpondyloarthritis Studies and TreatmentsInflammatory Bowel Disease
Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings | Litcius